Transcode Total Current Assets from 2010 to 2026
| RNAZ Stock | USD 9.79 -0.01 -0.10% |
Total Current Assets | First Reported 2019-12-31 | Previous Quarter 8.2 M | Current Value 4.8 M | Quarterly Volatility 7.1 M |
Macro event markers
Review Transcode Therapeutics financial statements over time to add context on performance and capital structure. Key drivers include Depreciation And Amortization of 315.4 K, Interest Expense of 29.3 K or Selling General Administrative of 6.5 M along with ratios such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. This view complements Transcode Therapeutics Valuation and Volatility modules.
Transcode | Total Current Assets | Build AI portfolio with Transcode Stock |
Analyzing Transcode Therapeutics's Total Current Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Current Assets has evolved provides context for assessing Transcode Therapeutics's current valuation and future prospects.
Latest Transcode Therapeutics' Total Current Assets Growth Pattern
Below is the plot of the Total Current Assets of Transcode Therapeutics over the last few years. It is the total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle. Transcode Therapeutics' Total Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Assets | 10 Years Trend |
|
Total Current Assets |
| Timeline |
Transcode Total Current Assets Regression Statistics
| Arithmetic Mean | 3,501,665 | |
| Geometric Mean | 836,357 | |
| Coefficient Of Variation | 166.84 | |
| Mean Deviation | 4,182,449 | |
| Median | 214,646 | |
| Standard Deviation | 5,842,114 | |
| Sample Variance | 34.1T | |
| Range | 22.5M | |
| R-Value | 0.57 | |
| Mean Square Error | 24.7T | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | 656,219 | |
| Total Sum of Squares | 546.1T |
Transcode Total Current Assets History
Stock Overview, Methodology & Data Sources
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. The stock overview for Transcode Therapeutics summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 6.3. Transcode Therapeutics has a market cap of 8.99 M, ROE of -17.63%.
Methodology
Unless otherwise specified, financial data for Transcode Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Transcode (USA Stocks:RNAZ) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Transcode Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Transcode Therapeutics is covered by 1 analyst. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Transcode Stock Analysis
A structured review of Transcode Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Transcode Therapeutics Stock. Outlined below are key reports that provide context for Transcode Therapeutics Stock:Review Transcode Therapeutics Correlation against competitors for Transcode Therapeutics. This adds peer-relative context. For information on how to trade Transcode Stock refer to our How to Trade Transcode Stock guide.Analysis related to Transcode Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
The market value of Transcode Therapeutics is measured differently than book value, which reflects Transcode accounting equity. Transcode Therapeutics' market capitalization is 8.99 M. With a P/B ratio of 6.3, the market values Transcode Therapeutics well above its book equity. Enterprise value stands at 3.21 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Note that Transcode Therapeutics' intrinsic value and market price are different measures derived from different inputs. For Transcode Therapeutics, key inputs include a P/B ratio of 6.3, and ROE of -17.63%. By contrast, market price reflects the level where buyers and sellers transact.